Electrosensitivity SupportGUEST AUTHOR

A Comparative Review of the Leading Recommendations for Electromagnetic Sensitivity

Electromagnetic Sensitivity

This article reviews the research and clinical thinking to date as to treatment to help and manage electromagnetic sensitivity (ES), also referred to as electromagnetic hypersensitivity (EHS), IDC code W90, a novel neurological syndrome produced by overexposure to electromagnetic radiation, to which it appears some individuals are more susceptible than others.

It analyses, compares and contrasts the recommendations of:
1) Professor Dominic Belpomme in France (pictured here on left);
2) Dr Andrew Tresidder, Medical Adviser to ES-UK (centre);
3) Professor Martin Pall of Washington State University, USA (on right).

A review of these recommendations is also cause for the evaluation of an additional treatment strategy in the light of these protocols.

Belpomme is one of the best known clinicians working with this condition. His regime has four components –

I) personalised nutriceutical regime to maximise detoxification processes;

II) nutritional components needed to rebuild / restore neurological tissues, eg omega-3,6 oils, whether in the diet or through supplementation;

III) agents to restore and/or increase cerebral vascularisation; either ginko biloba, or for nonresponders, fermented papaya preparations (the latter would be active in Category I as well as Category III).

IV) measures to avoid recurrence; practical measures such as avoidance of electromagnetic radiation (EMR) and/or shielding, and medical measures in the case of Belpomme, in the form of anti-inflammatories and anti-histamines

The regimes of Dr Andrew Tresidder (UK) and of Prof Martin Pall (USA) share with this components I and II; and to a more limited extent, component IV. All three thinkers agree on the use of maximising detoxification pathways, which may be subject to either acquired or genetic limitations. All three agree that those who are EHS should minimise their exposure to EMR through practical steps (category IV).

Belpomme however has gone beyond this common ground and introduced two additional measures. Firstly, he has created techniques for measuring cerebral blood flow, which he finds to be impaired by EMR exposure and accordingly he prescribes treatments in category III above, to restore this
reduced blood flow. (Author’s note: this temporary reversible reduction of cerebral perfusion has common ground with migraine{often a co-morbidity and/or misdiagnosis} and perhaps with TIAs although different in the usual
location affected). Secondly, in recognising the risk of recurrence he not only advocates practical measures but goes beyond this to prescribe drugs intend to reduce response and/or reactivity.

The author’s own opinion is that in this last category (IV above), Belpomme may not yet have gone far enough and that additional measures might be tested to potential benefit; and it is here that my interest in calcium channel blockers arises. My hypothesis is that in the light of the Pall research
identifying voltage-gated calcium channels as the mechanism of pathophysiology in EHS is that any drug of this class would function in category IV above, although in the absence of other indications,
those favouring the peripheral circulation would be preferred over those targeting cardiac function.

This thinking is reinforced by my empirical observations that EMR exposure in those who are EHS produces reduction in peripheral circulation as evidenced by the characteristic grey-tinged pallor of
the face and cold extremities, whereas when effective shielding is deployed, the hands and feet feel warm and the colour and appearance of the face suggests improved perfusion. Further and beyond my interest is in the use specifically of nimodipine as it would be likely to function in category III as well as category IV, and could therefore offer a greater benefit to agents
in category III alone.

Dr Williams thanks the Society of Authors (UK) for its kind support for the writing of this article.

Copyright, Dr Juliet Williams MB BS DSH, Certified EMF Expert Consultant
03.04.2020


Other Popular Articles by Dr Williams:
Electrosensitivity the Modern Plague: Beginners’ Guide –
The Phenomenon, Pathophysiology, Treatment and Management.

Update by Dr Williams:
A very significant article by Belpomme published March 11, 2020 showing that EHS is due to reduced blood flow in the middle cerebral artery / arteries, so it is a circulatory and a not a psychological disorder. This may have significant policy ramifications, but does not (yet) change the treatment recommendations he makes. Details are here: https://www.mdpi.com/1422-0067/21/6/1915


Dr Juliet Williams qualified MB BS from Kings College London in 1989 and has taught at Bristol University’s medical school (home to leading UK experts on electromagnetic radiation Professor Dennis Henshaw and Dr Andrew Tresidder) and on many other health-related courses. She has a long standing interest in environmental influences on health and is now a specialist adviser on environmental illness. To increase her knowledge of the effects of radiation and how to help people mitigate these, she successfully completed EMF Experts’ consultancy training, winning the Blue Ribbon top in her group and becoming the first EMF Experts Consultant in Britain.

Dr Juliet Williams: EMF Professional Directory Listing


close
We keep your data private and share your data only with third parties that make this service possible. See our Privacy Policy for more information.
Tags
Show More

Related Articles

Back to top button
Close
Close